On 20 AUG NovaBay Pharmaceuticals, Inc. (NYSEMKT:NBY) announced that its NVC-422 ophthalmic formulation did not meet the primary or secondary endpoints in a Phase 2 clinical study in patients with adenoviral conjunctivitis. NovaBay Pharmaceuticals, Inc. (NYSEMKT:NBY) belongs to Healthcare sector. Its weekly performance is -36.00%. On last trading day company shares ended up $0.80. NovaBay Pharmaceuticals, Inc. (NYSEMKT:NBY) distance from 50-day simple moving average (SMA50) … Continue reading Active Stocks: NovaBay Pharmaceuticals (NYSEMKT:NBY), Novatel Wireless (NASDAQ:NVTL), Chicago Rivet & Machine (NYSEMKT:CVR), CBS Corporation (NYSE:CBS), Umpqua (NASDAQ:UMPQ)